Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-HNSCC
2023-506294-36-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Volrustomig sequential therapy with Observation (2 arms). Primary endpoint: Progression-Free Survival (PFS) in PD-L1 expressing tumors. Planned start Apr 2024; status: authorised.
02
Drugs
volrustomig
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-506294-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506294-36-00.